Fig. 1From: Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [225Ac]Ac-DOTA-TDA-Lipiodol® against hepatic tumorsBiodistribution of [225Ac]Ac-DOTA-TDA-Lipiodol® of select organs/tissues in: A Tumor-bearing male mice at 35-min, 6, 24, 72, 144, and 240-h: B Tumor-bearing female mice at 35-min, 6, 24, 72, 144, 240, and 504-h: C Non-tumor bearing rats at 1, 24, 72, and 144-hBack to article page